Carregant...
Miniatura

Tipus de document

Article

Versió

Versió publicada

Data de publicació

Llicència de publicació

cc-by (c)  Juan Lazaro-Navarro et al., 2025
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/219304

Inhibiting H3K27 Demethylases Downregulates CREB-CREBBP, Overcoming Resistance in Relapsed Acute Lymphoblastic Leukemia

Títol de la revista

Director/Tutor

ISSN de la revista

Títol del volum

Resum

Background: CREB binding protein (CREBBP) is a key epigenetic regulator, altered in a fifth of relapsed cases of acute lymphoblastic leukemia (ALL). Selectively targeting epigenetic signaling may be an effective novel therapeutic approach to overcome drug resistance. Anti-tumor effects have previously been demonstrated for GSK-J4, a selective H3K27 histone demethylase inhibitor, in several animal models of cancers. Methods: To characterize the effect of GSK-J4, drug response profiling, CRISPR-Dropout Screening, BH3 profiling and immunoblotting were carried out in ALL cell lines or patient derived samples. Results: Here we provide evidence that GSK-J4 downregulates cyclic AMP-responsive element-binding protein (CREB) and CREBBP in B-cell precursor-ALL cell lines and patient samples. High CREBBP expression in BCP-ALL cell lines correlated with high GSK-J4 sensitivity and low dexamethasone sensitivity. GSK-J4 treatment also induced Bcl-2 and Bcl-XL dependency and apoptosis. Conclusions: This study proposes H3K27 demethylase inhibition as a potential treatment strategy for patients with treatment-resistant ALL, using CREBBP as a biomarker for drug response and combining GSK-J4 with venetoclax and navitoclax as synergistic partners.

Matèries (anglès)

Citació

Citació

LAZARO NAVARRO, Juan, ALCON, Clara, DOREL, Mathurin, ALASFAR, Lina, BASTIAN, Lorenz, BALDUS, Claudia, ASTRAHANTSEFF, Kathy, YASPO, Marie-laure, MONTERO BORONAT, Joan, Cornelia Eckert. Inhibiting H3K27 Demethylases Downregulates CREB-CREBBP, Overcoming Resistance in Relapsed Acute Lymphoblastic Leukemia. _Cancer Medicine_. 2025. Vol. 14, núm. 1, pàgs. 1-7. [consulta: 23 de gener de 2026]. ISSN: 2045-7634. [Disponible a: https://hdl.handle.net/2445/219304]

Exportar metadades

JSON - METS

Compartir registre